Australia - English - Department of Health (Therapeutic Goods Administration)

australian by nature pty ltd - propolis dry extract, quantity: 400 mg (equivalent: lead, qty 1 microgram; equivalent: propolis, qty 2 g) - capsule, soft - excipient ingredients: grape seed oil; glycerol; iron oxide black; white beeswax; iron oxide red; gelatin; soya oil; lecithin; purified water; carob pod; hydrogenated coconut oil - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support general health and wellbeing ; maintain/support immune system health

Australia - English - Department of Health (Therapeutic Goods Administration)

australian naturopathics pty ltd - ascorbic acid,astragalus membranaceus,calcium ascorbate,calcium carbonate,citrus bioflavonoids extract,echinacea purpurea,hesperidin,magnesium carbonate hydrate,olea europaea,potassium ascorbate,rosa canina,sodium ascorbate,selenomethionine,vitis vinifera,zinc ascorbate -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - itraconazole - oral capsule - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - itraconazole - oral capsule - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genesis pharmaceuticals ltd - itraconazole - oral capsule - 100mg

Australia - English - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 32568 - stereotactic surgery system, neurological - alpha omega neurosmart system is intended to be used in assisting neurosurgeons in the operating room during functional neurosurgery and to record from and stimulate brain motor and sensory neurons to aid in the placement of depth electrodes.

United States - English - NLM (National Library of Medicine)

grifols usa, llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - prolastin-c is an alpha1 -proteinase inhibitor (human) (alpha1 -pi) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1 -pi (alpha1 -antitrypsin deficiency). prolastin-c increases antigenic and functional (anti-neutrophil elastase capacity, anec) serum levels and antigenic lung epithelial lining fluid levels of alpha1 -pi. limitations of use - the effect of augmentation therapy with any alpha1 -pi, including prolastin-c, on pulmonary exacerbations and on the progression of emphysema in alpha1 -pi deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. - clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with prolastin-c are not available. - prolastin-c is not indicated as therapy for lung disease in patients in whom severe alpha1 -pi deficiency has not been established. prolastin-c is contraindicated in: - iga deficient patients w

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 16 mg in 1 ml - aralast np is an alpha1 -proteinase inhibitor (alpha1 -pi) indicated for chronic augmentation therapy in adults with clinically evident emphysema due to severe congenital deficiency of alpha1 -pi (alpha1 -antitrypsin deficiency). aralast np increases antigenic and functional (anti-neutrophil elastase capacity, anec) serum levels and antigenic lung epithelial lining fluid levels of alpha1 -pi. the effect of augmentation therapy with any alpha1 -pi, including aralast np, on pulmonary exacerbations and on the progression of emphysema in alpha1 -antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy with aralast np or aralast are not available. aralast np is not indicated as therapy for lung disease in patients in whom severe congenital alpha1 -pi deficiency has not been established. aralast np is contraindicated in immunoglobulin a (iga) deficient patients with antib

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

aimco kr australia pty ltd - alpha-cypermethrin - unknown - alpha-cypermethrin pyrethroid active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sinon australia pty limited - alpha-cypermethrin - unknown - alpha-cypermethrin pyrethroid active 0.0 - active constituent